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ABSTRACT
Current diagnostics of dry eye disease are unable to identify the multiple complex causes
of dry eye, thereby limiting the proper treatments of the disease. The tear glycoprotein lacritin
has been reported to be decreased in dry eye patients, specifically those with Sjӧgren’s syndrome
associated dry eye. Therefore, the use of lacritin in a diagnostic test for dry eye could improve
the current diagnostics available. Western blot assays have revealed the presence of an active
lacritin monomer as well as an inactive tissue transglutaminase cross-linked polymer in human
tears. A third isoform of lacritin, the splice variant lacritin-c, has also been detected in human
tears. Using a diagnostic multiplex western blot assay, the three lacritin isoforms were
quantitated in forty samples of human tears from twenty adults and analyzed using JMP
software. This provided a baseline distribution of percent lacritin in human tears that will be used
in future lacritin clinical trials.

INTRODUCTION
One of the most common problems in ophthalmology is dry eye disease; however, diagnosis
is difficult due to multiple causes of the disease and lack of a definitive diagnostic test.
Currently, there is no consensus on the guidelines for diagnosis, and the causes of dry eye are
complex, ranging from premenopausal symptoms in women to altered corneal innervation
(McNamara et al., 2016). Dry eye consists of a wide spectrum of dysfunctions and there is no
specific separation between an eye designated as “normal” and an eye that presents dry eye.
Additionally, the current diagnostic tests for dry eye are not standardized, making comparison
between patients difficult (Savini, 2008). The most commonly used diagnostic tool for dry eye
diagnosis is the Schirmer tear test (STT) which measures total tear secretion by inserting
Schirmer tear test strips into the temporal lower conjunctive sac to measure the rate of tear
4

production (Boyd, 2018). After five minutes, the strip is removed, and wetting is recorded in
millimeters (mm). Normal tears are diagnosed by wetting over 10mm, and dry eye tears are
diagnosed by wetting less than 10mm. Unfortunately, there are multiple issues with using the
Schirmer tear test that include low reproducibility, sensitivity, frequent discomfort, difficulty
performing tests in children, and potential injury to conjunctiva and cornea (Salomon-Ben Zeev
et al., 2014). Due to varying diagnostics and causes for dry eye there is a need for a reproducible
test for the disease.
One of the emerging technologies for the diagnosis of dry eye is the use of tear biomarkers to
analyze tear protein patterns and identify dry eye in a protein-specific manner. The tear
glycoprotein, lacritin, has demonstrated potential as a protein biomarker for dry eye (Karnati et
al., 2013). Lacritin is a prosecretory mitogenic protein that is known to promote basal tearing and
exhibits cytoprotective activity (Wang et al., 2015). Structurally, lacritin has a molecular weight
of 12.3 kDa, an isoelectric point of 5, and consists of 119 amino acids; tertiary structure of
lacritin consists of two alpha helices, one amphipathic, and one that supports ligand-ligand
binding (Ma et al., 2008). The lacritin gene contains 5 coding exons and 4 noncoding introns.
The splice variant, lacritin-c, lacks exons 4 and 5 entirely and has sequences encoding 39 amino
acids found in intron 3 (McKown et al., 2010). When cleaved, lacritin releases the amphipathic
a-helical fragment, which creates bactericidal activity of tears by promoting metabolic stress and
eventual bacterial death (McKown et al., 2014).
Lacritin promotes ocular health but is seen to be downregulated in dry eye and other dry eye
related diseases. An example of a dry eye related disease with a connection to lacritin is
Sjӧgren’s syndrome, which has been linked to low levels of lacritin (McNamara et al., 2016).
Sjӧgren’s syndrome (SS) is an autoimmune disease in which dry eye is one of the main
5

symptoms, and currently there is no cure for this disease. However, when lacritin is present in
sufficient amounts for healthy individuals, the protein restores corneal homeostasis and promotes
basal tear secretion, as well as, epithelial cell proliferation (Karnati et al., 2016),(Wang et al.,
2006). Therefore, lacritin demonstrates an inverse relationship to dry eye symptoms.
Because of the relationship between lacritin and dry eye, lacritin in ocular disease has been
studied to determine the use of lacritin as a potential therapeutic. In a study comparing lacritin
treatment in rabbits with cyclosporin and artificial tears, lacritin was found to increase basal
tearing in rabbits, while the other treatments were unable to match the same results (Samudre et
al., 2011). Another study utilized a dry-eye treatment consisting of thermo-responsive lacritin
combined with an elastin-like polypeptide, which increased tear secretion in mice (Wang et al.,
2015). Therefore, lacritin can promote natural tear secretion in dry eye when topically applied.
Additionally, lacritin has demonstrated protective activities after corneal epithelia exposure to
benzalkonium chloride (BAK), a preservative found in eye drops. BAK causes ocular surface
inflammation and toxicity, but when lacritin is applied to corneal epithelia exposed to BAK,
there is increased cell proliferation, suggesting the use of lacritin as a treatment for BAK
exposure (Feng et al., 2014). This protective role of lacritin was also shown to alleviate apoptosis
of lipopolysaccharide challenged corneal epithelial cells (Vantaku et al., 2016). These studies
demonstrate lacritin’s potential use as a biotherapeutic, as lacritin activity targets the causes of
dry eye rather than treating the symptoms (Karnati et al., 2013).
Sjӧgren’s syndrome, an autoimmune disorder characterized by severe dry eye, has been
shown to have a strong relationship with lacritin. In a previous study, SS patients and normal
controls were assayed for lacritin proteins by western blot analysis, which revealed that
monomeric lacritin was downregulated in SS patients when compared to normal controls
6

(Vijmasi et al., 2014). In another study with SS patients, active tear lacritin was reduced in SS
patients when compared to age matched controls, and reduced levels of lacritin were correlated
to dry eye symptoms in SS patients (McNamara et al., 2016). Thus, the relationship between SS
associated dry eye and lacritin suggests that the protein has potential as both a diagnostic
biomarker and a topical therapeutic for SS dry eye.
Herein is reported the application of a multiplex western blot assay to quantify tear lacritin
isoforms in twenty healthy adults. These isoforms consist of monomeric lacritin, the splice
variant lacritin-c, and a cross-linked form of lacritin formed from an inactive tissue
transglutaminase cross-linked polymer, which negatively regulates lacritin activity (Velez V et
al., 2013). Tear samples from twenty healthy adults were eluted and analyzed by multiplex
western blots. This was performed in preparation for receipt of samples from the phase 2 trial of
LacripepTM in Sjӧgren's syndrome Dry Eye and from a non-interventional study of lacritin from
healthy volunteers. Samples from both the right (oculus dexter-OD) and left (oculus sinister-OS)
eyes were collected from both male and female subjects of varying ages. By quantitating
different forms of lacritin among twenty healthy subjects, we can provide a baseline for future
analysis of tear lacritin proteins in diseases such as Sjӧgren’s syndrome.

MATERIALS AND METHODS
Collection and Elution of Tears
Normal human tears were collected using Schirmer tear test strips that were placed in
cryotubes and stored at -20° C at the University of California San Francisco (UCSF). All
activities followed the guidelines set by the Declaration of Helsinki and approval by the UCSF
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Committee for Human Research, as well as HIPPA laws. Informed consent was obtained from
all subjects.
Once the tear samples were collected, the Schirmer strips were shipped on dry ice and
stored at -60°C until thawed for elution. For elution, sixty microliters of phosphate buffer saline
(PBS) were loaded onto the thawed Schirmer strips placed in spin baskets inserted into
microcentrifuge tubes. Tubes were incubated for twenty minutes at room temperature and then
centrifuged at 13,000 rotations per minute (RPM) for an additional ten minutes at 4°C. The
eluted products were analyzed with the Bicinchoninic Acid Assay (BCA) for determination of
total protein concentration (µg/mL) eluted from each tear sample.
Bicinchoninic Acid Assay (BCA)
The Thermo Scientific Pierce BCA Protein Assay Kit was utilized to determine total
protein concentration of each tear sample against a protein standard. Tear samples were loaded in
duplicate into a 96 well microtiter plate along with bovine serum albumin (BSA) standards
ranging from 0 mg/mL to 2.0 mg/mL. Samples and standards were loaded in volumes of 10uL
and analyzed at 570 nm using a spectrophotometer, following a thirty-minute reaction with
working reagent at 37°C. Unknown concentrations of total protein in each tear sample were
identified in mg/mL after comparison with absorbance values and known concentrations
generated through a BSA standard curve.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western
Blots
Tear samples were normalized to 400 µg/mL and loaded onto Any kD™ MiniPROTEAN® TGX™ Precast Protein Gels (Bio-Rad) and electrophoresed at 200 volts via
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). For assay
8

validation, 40 tear samples were divided into 5 sets (101-104, 105-107&109, 110-113, 108&114116, 117-120 OD, OS) and each set was run in duplicate. Each gel was transferred to
nitrocellulose (Protran BA 83; Whatman, Dassel, Germany) using a trans-blot apparatus run at
100 volts for one hour (Appendix B). Blots were stored at 4°C until probed with antibodies.
For development, the blots were washed for ten minutes with phosphate buffer saline
and 0.3% tween-20 (PBS-T) for a total of four washes at ten minutes each. Blots were incubated
with either anti-Lacritin N-term rabbit polyclonal antibodies (1:1500 dilution in PBS-T) or antiLacritin I3 rabbit polyclonal antibodies (1:1500 dilution in PBS-T), developed from BioSynthesis Inc (Lewisville, TX). N-term antibodies recognize all three lacritin isoforms, while I3
antibodies recognize only the splice variant and cross-linked isoforms of lacritin. The incubation
took place for one hour at room temperature, and blots were rinsed with PBS-T for an additional
four washes of ten minutes each, then incubated again for one hour with fluorescently labeled
goat anti-rabbit antibodies (1:12,500 dilution in PBS-T), followed by four washes with PBS-T at
10 minutes each.
Imaging and Quantitation of Lacritin Isoforms
Blots were imaged on a LiCor Odyssey CLx imaging system. The Odyssey CLx utilizes
two lasers that scan the blots twice, once using each laser’s high wavelength (800nm), and
another using each laser’s low wavelength (700nm). These scans from each laser come together
to form one image (Bouzid, Ahmed, Lesiak, 2013). Using ImageSoftware Lite, quantitation of
lacritin isoforms was determined based on relative signal obtained from the Odyssey CLx image.
Using a standard curve generated from recombinant lacritin standards of known concentrations
on each blot, nanograms (ng) of lacritin were calculated. From the nanograms of lacritin and the
nanograms total protein, the percent of total lacritin and individual lacritin isoforms were also
9

calculated. The lacritin percentages among the samples were distributed using a quartile system
obtained from JMP software.

RESULTS
Optimization of the Multiplex Western Blot Assay
In this study, the multiplex western blot assay was optimized to determine the most
efficient antibody dilutions, as well as, concentrations of both recombinant lacritin standards and
human tear samples to be used in the western blot. The LI-COR Odyssey CLx imaging system,
used to detect the presence of each lacritin isoform, demonstrated that primary antibody dilutions
of 1:1500 and secondary antibody dilutions of 1:12,500, as well as, loaded samples of 400µg/mL
displayed the most clear and distinct western bands to be used in quantitation. This allowed for
more precise quantitation of each lacritin isoform, providing accurate identification for the
distribution of mass and percent lacritin isoforms throughout the forty samples.
Antibodies Detect Different Isoforms of Lacritin in Human Tears
To detect lacritin isoforms in the multiplex western blot assay, antibodies were produced
that would identify the monomeric, cross-linked, and splice variant isoforms. The lacritin gene
contains five coding exons separated by four introns which produces the mature monomeric
protein of 119 amino acids found in human tears. The splice variant, lacritin-c contains exons 2
and 3 fused in-frame to 39 amino acids of intron 3, which produces a truncated protein of 104
amino acids also found in human tears (unpublished data). Rabbit polyclonal antibodies were
produced against the first 22 amino acids of exon 2 (N-Term Antibody) and 31 amino acids of
intron 3 (I3 Antibody) (Figure 1A).
One western blot of six tear samples and recombinant lacritin was challenged with antilacritin N-Term Antibody, and a second blot with the same samples was challenged with anti10

lacritin I3 Antibody (Figure 1B and 1C). Western blots developed by fluorescent secondary
antibodies and imaged by the LI-COR Odyssey CLx imaging system revealed the anti-lacritin NTerm antibodies detected full length tear lacritin (monomer), recombinant lacritin, and lacritin-c
(Figure 1B) while I3 antibodies only detected lacritin-c specific sequences (Figure 1C). Both
antibodies detected cross-linked forms of lacritin (Figure 1B & 1C). These antibodies were then
used to detect the lacritin isoforms from the twenty samples shipped from UCSF.

Figure 1. Antibodies Detect Different Isoforms of Lacritin in Human Tears. (A) Anti-lacritin antibodies
were produced against N-term sequences and unique sequences of the splice variant lacritin-c. (B) N-term
antibodies detect monomeric lacritin, cross-linked lacritin, lacritin-c in human tears and recombinant
lacritin produced in bacteria by Western blot analysis. (C) Antibodies unique to intron 3 of lacritin (I3)
detect only lacritin-c and cross-linked forms of lacritin-c by Western blot analysis.
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Quantitation of Tear Lacritin Isoforms by Western Blot
To quantify the tear lacritin isoforms on western blots, known masses of purified lacritin
(ng) were run along with tear samples on the same blot and used to generate a standard curve. A
western blot containing six human tear samples and the purified recombinant lacritin standards
was probed with anti-lacritin N-Term antibodies, developed with fluorescent secondary antibodies,
and imaged by the LI-COR Odyssey CLx imaging system (Figure 2A). The LI-COR Odyssey CLx
imaging system produced a signal number for each band identified on the blot generated by the
near-infrared fluorescent detection of the used secondary antibodies (Figure 2A). Near-infrared
fluorescent detection of purified recombinant lacritin standards were plotted against the known
masses of those same standards to generate a standard curve of signal versus lacritin (ng) (Figure
2B). Specific protein bands for lacritin, lacritin-c, and cross-linked polymers of lacritin from
human tears were quantified by near-infrared fluorescent signals, and a linear regression equation
(y=1.09x) generated from recombinant lacritin was used to approximate the masses of tear lacritin
proteins (ng) (Figure 2C).
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Figure 2. Western Blot Quantitative Analysis. (A) Human tear samples and recombinant lacritin
challenged with anti-lacritin N-Term primary antibodies and fluorescent secondary antibodies (B)
Decreasing concentrations of recombinant lacritin were quantified using near-infrared fluorescent detection
and plotted against known masses of recombinant lacritin (ng) to generate a standard curve of signal versus
lacritin (ng). (C) Specific protein bands for lacritin, lacritin-c, and cross-linked polymers of lacritin from
human tears were quantified and a linear regression equation was used to approximate concentrations of
tear lacritin proteins.

Assay Validation with Tear Samples from 20 Adults
In order to validate the immunoassay, tear samples from both eyes (OD and OS) of
twenty adults were first analyzed for total eluted protein. Total protein concentration of the
eluted samples was determined using the bicinchoninic acid assay (BCA) (Appendix A). The
distribution of protein concentrations (Figure 3A) was divided into quartiles using JMP software
(Figure 3B). The 25th quartile, median (50th) quartile, and 75th quartile total protein
concentrations were 1.5025 mg/mL, 1.92 mg/mL, and 2.3175 mg/mL, respectively (Figure 3B).
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Figure 3. Distribution of Total Eluted Protein from 20 Adults (40 samples). Distribution of eluted
protein concentrations versus sample number as a scatter plot (A) and the distribution of eluted protein
based on a quartile system (B). The standard deviation is represented to the right of the curve along with
tick marks denoting the 5th and 95th percentiles of the curve. Additionally, the curves are divided into
quartiles (25th, 50th, and 75th) as denoted by the box to the right of the curve. The diamond within this
quartile box represents the mean of the samples, the middle of the diamond is the mean and the tips of this
diamond represent the certainty of the mean.

Western Blot Analysis of Tear Samples from 20 Adults
To separate and detect the lacritin isoforms, tear samples were loaded on Any kD™
Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad), electrophoresed at 200 V, and
transferred to nitrocellulose (Protran BA 83; Whatman, Dassel, Germany). Blots were blocked
with PBS + 0.3% Tween 20 (PBST), incubated with anti-Lacritin N-Term (1:500 dilution in
PBST) for 1 hour at room temperature, rinsed with PBST, and incubated for 1 hour at room
temperature with fluorescently labeled goat anti-rabbit antibodies (1:12,500 dilution in PBS-T).
Western blots were imaged with a LI-COR Odyssey CLx imaging system which revealed the
presence of each lacritin isoform: cross-linked lacritin (75kDa), monomeric lacritin (25kDa), and
the lacritin splice-variant (15kDa) (Figure 4).
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Figure 4. Western Analysis of Lacritin Isoforms from 20 Adults. Lacritin isoforms from tear samples
of both right (OD) and left (OS) eyes were detected through western blots for samples 101-120. Isoforms
are denoted to the right with corresponding molecular weights in kDa denoted to the left: cross-linked
lacritin (75 kDa), monomeric lacritin (25 kDa), and splice variant lacritin (15 kDa). Schirmer tear test
values (STT) are given for each sample (mm absorbed) in their corresponding lane at the bottom of each
western blot.

Quantitation of Tear Lacritin Isoforms from 20 Adults
To quantify the nanograms and percent lacritin isoforms, western blot images obtained
from the LiCor Odyssey CLx imaging system were analyzed using ImageSoftwareLite. This
produced values for each western band using relative fluorescent signals obtained at the 800nm
wavelength (Figure 5). Relative signals of decreasing concentrations of recombinant lacritin run
on each gel were used to generate a standard curve (Figure 5). The standard curve allowed for the
quantitation of total lacritin and each lacritin isoform in nanograms (Figure 5), which were then
used in conjunction with total eluted protein to determine total lacritin (ng) and the percent of each
15

lacritin isoform present within each sample (Figure 5). Western blots of 40 tear samples and
recombinant lacritin showing the relative signals is in Appendix B. An example is given of the
quantitation and a summary table of the data generated for samples 101-104 (OD and OS) (Figure
5).

Figure 5. Quantitation of Tear Samples 101 – 104. Lacritin isoforms from both the right (OD) and left
(OS) eyes in each sample, as well as, recombinant lacritin standards were quantitated using relative signal
to generate a standard curve. This was compared to total eluted protein to determine molarity, nanograms,
and percent lacritin in each sample expressed as ng lacritin per 100ng total protein.

Distribution of Total Lacritin Isoforms from 20 Adults
To exhibit the potential for a baseline distribution of nanograms as well as percentages of
lacritin isoforms, the obtained masses and percentages from the western blots were distributed in
a quartile system using JMP software (Figure 6) (Figure 7). Nanograms of combined lacritin
isoforms and percent lacritin of each isoform were determined from the recombinant lacritin
16

standard curves generated in the quantitated western blots (Appendix B). The median total
lacritin in nanograms was 211.5 ng and the median total percent lacritin was 7.24% (Figure 6)
(Figure 7). The 25th quartiles and 75th quartiles for total nanograms of lacritin and total percent
lacritin were 136.5 ng, 326.25 ng, and 5.43%, 10.21%, respectively (Figure 6) (Figure 7). For
each of the isoforms (cross-link, monomer and splice-variant) the median percentages were
2.04%, 2.435% and 1.97%, respectively (Figure 7).

Figure 6. Distribution of Total Lacritin (ng) for Samples 101-120. The distribution of total lacritin
(ng) (A) and the distribution of total lacritin (ng) by quartile system (B) are given. The standard deviation
is represented to the right of the curve along with tick marks denoting the 5th and 95th percentiles of the
curve. Additionally, the curves are divided into quartiles (25th, 50th, and 75th) as denoted by the box to the
right of the curve. The diamond within this quartile box represents the mean of the samples; the middle of
the diamond is the mean and the tips of this diamond represent the certainty of the mean.
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Figure 7. Distribution of Percent Lacritin Isoforms and Total Percent Lacritin for Samples 101120. The standard deviation is represented to the right of the curves along with tick marks denoting the 5th
and 95th percentiles of the curve. Additionally, the curves are divided into quartiles (25th, 50th, and 75th) as
denoted by the box to the right of the curve. The diamond within this quartile box represents the mean of
the samples, the middle of the diamond is the mean and the tips of this diamond represent the certainty of
the mean.

DISCUSSION
A multiplex western blot immunoassay that detects three isoforms of human tear lacritin
was validated for future use in human clinical trials. Quantitation of the lacritin isoforms and
recombinant lacritin with the LI-COR Odyssey CLx imaging system was used to calculate
nanogram and percent total protein concentrations of three lacritin isoforms found in human
tears. These masses and percentages were distributed in an example baseline distribution which
18

could potentially provide diagnosis for lacritin-deficient dry eye. This immunoassay will be used
in a LacripepTM clinical trial to determine the distribution of tear lacritin isoforms˗˗˗before and
after topical application of a lacritin peptide on dry eye patients.
Validation of this diagnostic western blot assay is essential in demonstrating the potential
use of lacritin as a biomarker for dry eye associated diseases. Application of this assay on tear
samples obtained from patients suffering from dry eye may provide a diagnostic test for future
clinical use. N-Term and I3 antibodies demonstrated that three distinct lacritin isoforms may be
visualized (Figure 1). All three isoforms of lacritin were then detectable in western blots using
those anti-lacritin primary antibodies followed by fluorescent antibodies (Figure 4). Additionally,
all three lacritin isoforms were quantifiable using the LI-COR Odyssey CLx imaging system
which was used to calculate nanograms as well as percentages of lacritin from a recombinant
lacritin standard curve run on the same blot (Figure 5). This allowed for the distribution of these
isoforms using a quartile system with JMP Software (Figure 7). Thus, the application of a
diagnostic western blot immunoassay was validated and the potential for lacritin as a diagnostic
biomarker for dry eye was demonstrated.
Tear film is a complex mixture of 183 extracellular proteins of which 4-5% of these
proteins are related to of dry eye disease (Laurie et al., 2008). By placing emphasis on ocular
proteins, protein therapeutics may be developed to treat the cause, rather than the symptoms of
ocular diseases, like dry eye. This is particularly true when studying the roles of proteins like
lacritin in the tear proteome. Lacritin has been shown to be deficient in varying forms of dry eye,
most notably, Sjӧgren’s syndrome dry eye (Karnati et al., 2013). When present in sufficient
amounts, lacritin increases basal tear secretion and has cytoprotective and mitogenic properties
(Ma et al., 2008). Therefore, the use of lacritin as a biomarker could make the diagnosis of
19

lacritin-deficient ocular disease possible and allow for the prescription of topical lacritin
treatments. A novel therapeutic, LacripepTM, is currently being analyzed in a human clinical trial
as an effective treatment for dry eye.
LacripepTM utilizes a synthetic 19 amino acid derivative of lacritin as a topical
therapeutic for a study in SS dry eye patients. After meeting exclusion and inclusion criteria, 201
patients, as well as age-matched controls, were recruited for a clinical trial (TearSolutions,
2017). In a triple-blind study to identify the efficacy of differing strengths of LacripepTM, 201
patients were divided into three groups, receiving either one of two LacripepTM ophthalmic
solutions of differing strengths or a placebo (TearSolutions, 2017). Patients were administered
their designated ophthalmic solution over four weeks, three times daily (TearSolutions, 2017).
Samples from these patients and age-matched controls were then collected on Schirmer strips
and shipped to James Madison University, where analysis of the tear samples will take place.
The multiplex western blot immunoassay will be used to identify the distribution of percent
lacritin isoforms in a quartile system, providing a baseline for future diagnosis of dry eye
patients.
Throughout this study a multiplex western blot assay was developed for the use in human
clinical trials to diagnose lacritin-deficient dry eye. By properly diagnosing dry eye patients
using lacritin as a protein biomarker, a lacritin therapeutic, LacripepTM, can be administered to
patients to treat the cause rather than the symptoms of their specific form of dry eye. Therefore,
the validated diagnostic western blot assay will contribute to the improvement of dry eye
diagnosis, providing many patients with relief from a disease with no previous consensus on
diagnosis and treatment.
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